News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG's Onbrez Plus Rival, Pfizer Inc. (PFE)'s Drug Boosts Lung Function



2/10/2011 7:36:34 AM

ZURICH, Feb 10 (Reuters) - Patients with a deadly lung disease who took Novartis's (NOVN.VX) Onbrez Breezhaler as well as Pfizer's (PFE.N) Spiriva HandiHaler had better lung function than those taking only the Pfizer treatment, studies showed.

Read at Reuters
Read at Wall Street Journal
Read at RTT News


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES